Latest News and Press Releases

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.

In the registrational clinical trial, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile, with ORR of 89.1% and DCR of 96.4%.

Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL.

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...

AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system,...

The collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chainClients to benefit from accelerated timelines, as well...

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.

First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”...

AUSTIN, Texas, Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As advanced biotech programs move closer to commercialization, fair-value adjustments under U.S. Generally Accepted...

Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle The transaction values Curium at circa $7 billion, representing the largest transaction in nuclear...